About Cutaneous Lymphoma

Yaupon Changes Name to Ceptaris Therapeutics, Inc.

Thu, 01/05/2012

MALVERN, PA (January 5, 2012) – Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today it has changed its name to Ceptaris Therapeutics, Inc., effective immediately. The new name is intended to reflect the recent changes in management and the Company’s ongoing transformation into a commercial organization. Ceptaris Therapeutics’ lead drug candidate, mechlorethamine gel is currently undergoing review by the U.S. Food and Drug Administration (FDA) for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).

“With our first investigational drug under review by the FDA, the Company is planning for entry into a commercial phase for the first time,” said Ceptaris Chairman of the Board and CEO Steve Tullman. “We have created a new name to reflect this evolution in our Company’s growth and development.”

The FDA previously granted Orphan Drug Status to this investigational drug. The new drug application (NDA) for Ceptaris' mechlorethamine gel was filed in July 2011.

In mid-2011, Steve Tullman was named Chairman of the Board and CEO and established a new management team that included leadership who previously worked with him at Ception Therapeutics, which was acquired by Cephalon, Inc. in April 2010.

About Ceptaris Therapeutics

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine gel widely available to relieve the signs and symptoms of this rare cancer. Please visit www.ceptaris.com for more information.

Media Contact:

Mike Beyer, Sam Brown Inc.

English French German Italian Portuguese Russian Spanish

This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.